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Abstract
Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the
outcome of therapy and of the development of comorbidities. In this review we aimed to evaluate the relationship
between plasma total antioxidant capacity (TAC) and peroxidation biomarkers, as well as their association with
dyslipidemia and systemic inflammation in psoriasis. The review of 59 case–control comparisons (from 41 studies)
and 17 interventions (from 13 studies) suggests that peroxidation markers are more sensitive than TAC in the
evaluation of oxidative stress in psoriasis. Although few studies investigated the effect of treatment on oxidative
stress, it seems that biological drugs could be the better choice in the treatment of psoriasis. However, considering
the limitations of TAC and plasma peroxidation markers, this review suggests that new methods should be
developed in order to evaluate systemic oxidative stress in psoriasis.
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Background
Psoriasis is a common, chronic inflammatory and
immune-mediated skin disease [1, 2].
In psoriatic patients, biomarkers could be relevant for
distinction between the different clinical variants of the
disease, for the assessment of disease activity and sever-
ity and for the prediction of the outcome of a thera-
peutic intervention [1, 2]. In recent years, the great
importance of the use of biomarkers for the prediction
of the development of comorbidities such as arthritis,
cardiovascular diseases (CVD) and metabolic syndrome
has been acknowledged [3–7]. In particular, soluble bio-
markers have the potential to be useful for screening pa-
tients with psoriasis for underlying psoriatic arthritis [2].
Chiu and Ritchlin [5] proposed a model to explain how
psoriatic arthritis originates from a cutaneous plaque.
The initial inflammatory events originate in the plaque
(activation of monocytoid dendritic cells, macrophages
and T cells) and lead to an increase of tumor necrosis
factor alpha (TNF-α) production. Activated T cells and
monocytoid dendritic cells circulate to lymph nodes,
joints, and bone marrow [5]. TNF-α overproduction is
highlighted in each compartment, but other inflamma-
tory cytokines, such as interleukin (IL)-12, IL-17, IL-22,
and IL-23 are also critically important [1, 5]. In particu-
lar, a linear relationship has been suggeted between
proximal inducers (IL-23 and IL-12) and the T-helper
(Th) cell activation [1]. IL-23 activates Th, which subse-
quently produce IL-17 and IL-22, whereas IL-12 induces
the Th1 response [1].
Both Th1 and Th17 cytokines induce an increased
generation of reactive oxygen species (ROS) [8], which is
involved in the pathogenesis of psoriasis [9]. In fact, in-
creased ROS production originates not only from ex-
ogenous agents, such as cigarette smoking [10], but also
from endogenous sources, such as the inflammatory re-
sponses of leucocytes involving NADPH-oxidase (NOX),
inducible nitric oxide synthase (iNOS) and myeloperoxi-
dase (MPO) activation during oxidative burst [8]. It is
known that leukocyte-mediated oxidation of the (LDL)
contributes to the pathogenesis of atherosclerosis [8].
Oxidized low density lipoproteins (oxLDL) have been
suggested to be markers of accelerated atherosclerosis in
rheumatoid arthritis and psoriatic arthritis, whereas vita-
min A, vitamin E and β-carotene seem to be associated
only to the presence of the autoimmune disorders [11].
In a case–control study on patients with psoriasis and
sex- and age-matched healthy volunteers, psoriatic skins
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were shown positive oxLDL staining, whereas there was
no staining in non-lesional skin samples from the same
subject [12]. Furthermore, the mean levels of cholesterol
(CHOL) and triglycerides (TG) in patients with psoriasis
were found to be significantly higher than those of
healthy subjects [12].
In this context, although psoriasis is traditionally con-
sidered a skin-specific inflammatory disease with the ex-
ception of coexisting psoriatic arthritis, it has been
recognised as a systemic disease and dyslipidemia is one
of the comorbidities in psoriatic patients [13–15]. There-
fore, the relationship of systemic biomarkers of oxidative
stress with lipid profile and inflammatory markers in
psoriasis is an interesting topic. The description of the
biomarkers of lipid, protein and DNA damage, as well
as of antioxidant defences has been recently reviewed
in the context of systemic lupus erythematosus [16]. Al-
though isoprostanes are the highly sensitive and specific
markers of oxidative stress in patients with psoriasis
[17], many studies reported measurements of other
markers of peroxidation, such as oxLDL, malondialde-
hyde (MDA), thiobarbituric acid reactive substance
(TBARS), peroxides, dienes and total oxidant capacity
(TOC), also named total oxidant status (TOS), as well
as the plasma total antioxidant capacity (TAC), also
named total antioxidant status (TAS), total antioxidant
response (TAR), antioxidant potential (AOP) or non-
enzymatic antioxidant capacity (NEAC) [18–62]. While
isoprostanes correlated with other markers of lipid per-
oxidation (e.g., TBARS) [17], in a review of human
intervention studies the isoprostanes levels were af-
fected neither by treatments (e.g. green tea, green tea
extracts, and epigallocatechin gallate), nor by study de-
sign (e.g. bolus or repeated administration), or when
NEAC increased after treatment [63]. On the other
hand, the majority of the interventions with green tea
and its supplements pointed out an increase of NEAC
(69 %, n = 22/32) [63]. Therefore, lipid peroxidation re-
sulted unrelated to TAC, probably because the latter
often measures the antioxidant capacity in an hydro-
philic environment [63]. In this review we aimed to
evaluate the relationship between these biomarkers, as
well as their association with dyslipidemia and systemic
inflammation in psoriasis.
Review
Case–control studies
A review of forty-one case–control studies [18–58]
(Table 1) has been performed. The number of subjects
of the studies ranged from 13 [33] to 516 [41]; some
studies reported separately data for mild, moderate and
severe psoriasis [22, 31, 32, 36, 42, 45], for active and in-
active psoriasis [46–49], for smokers and non smokers
[20, 30] or for subjects with and without metabolic
syndrome [55]. Therefore fifty-nine case–control com-
parisons were available from forty-one studies (Table 1).
These studies reported measurements of TAC (n = 33),
of markers of peroxidation (n = 54) and some of these
measured both markers (28) (Table 1). The majority of
the case–control comparisons pointed out an increase of
markers of peroxidation (88.9 %, 48/54), whereas de-
creased level of TAC were reported in 63.6 % of the
cases (21/33) (Table 1). Furthermore, the first study that
evaluated TAC in psoriasis reported that TAC in pa-
tients with psoriasis was significantly higher compared
to healthy controls [33]. Although, the percentage of
case–control comparisons reporting consistent results
between peroxidation markers and TAC was 85.7 %
(24/28), increased levels of peroxidation markers were
accompanied by increased markers of inflammation in
83.3 % (10/12) of the cases, whereas decreased TAC
was associated with increased inflammation only in
50 % (3/6) of the cases (Table 1).
In fact, although some studies found that severity
wise decrease in TAC levels [32, 36], Basavaraj et al.
[22] reported that there was no significant difference
in the average level of TAC of control, mild, moder-
ate and severe groups, despite the increase in serum
8-hydroxy-2’-deoxyguanosine (8-OHdG; a DNA dam-
age biomarker).
On the contrary, clinical severity of psoriasis, deter-
mined according to the Psoriasis Area Severity Index
(PASI) score, was significantly correlated with the con-
centrations of MDA [20, 32, 51]. Furthermore, the
serum levels of peroxidation markers (MDA, peroxide
and dienes) were observed to be significantly increased
from mild to moderate and from moderate to severe
psoriasis [20, 31, 32, 36, 46] and correlated positively
with the duration of the disease [20]. Also levels of
MDA in lesional tissues were significantly higher than
those in non-lesional tissues [51]. On the contrary,
Toker et al. [54] did not find a significant correlation be-
tween the percentage of psoriatic lesions and MDA. On
the other hand, significant differences were found in
TBARS levels between patient with active and inactive
psoriasis [47–49]. However it has been also reported that
there was no statistically significant difference in serum
TBARS between psoriatic patients and healthy volun-
teers, as well as no statistically significant correlation be-
tween disease duration, disease severity and serum levels
of TBARS [39]. Relhan et al. [46] comparing two groups
of patients, i.e. those with a PASI score of less than 6
and more than 6, did not find significant differences in
the two groups in plasma MDA during the acute phase.
However, plasma MDA levels were significantly higher
in the group of patients with PASI scores more than 6 in
the remission phase [46]. These patients achieved remis-
sion, however, their mean PASI score as well as MDA
Peluso et al. Journal of Biomedical Science  (2016) 23:52 Page 2 of 13
Table 1 Case–control studies reporting plasma or serum peroxidation biomarkers and Total Antioxidant Capacity in psoriasis:
association with inflammation and lipid profile
Ref. Case/control Peroxidation TAC Inflammation Lipid profile
[18] 100/100 ↑ MDA ↑ CHOL, LDL
↔ HDL, TG
[19] 100/100 ↑ MDA ↑VAP-1 ↑ CHOL, LDL
↔ HDL, TG
[20] 25/20: 10/10 smokers ↑ MDA
15/10 non-smokers ↑ MDA
[21] 29/18 ↑MDA/TBARS ↓ ↑ROS
[22] 30/10: 10 mild ↔
10 moderate ↔
10 severe ↔
[23] 35/25 ↑ MDA ↓
[24] 32/32 ↑ MDA
[25] 8/8 ↑ peroxides ↓
[26] 34/37 ↑ TBARS, oxLDL ↔ ↑ CRP ↑ CHOL, LDL, TG
↓ HDL
[27] 73/38 ↑ TBARS ↔ ↑CRP
[28] 67/35 ↑ TBARS
[29] 58/45 ↑ MDA ↓
[30] 54/62: 28/16 smokers ↑ TOS ↓ ↔ CHOL, LDL, HDL, TG
26/46 non-smokers ↑ TOS ↓ ↔ CHOL, LDL, HDL, TG
[31] 23/25: 12 mild (1) ↑ peroxides and dienes ↔ CRP ↔ CHOL, LDL, HDL, TG
11 severe (2) ↑ peroxides and dienes ↔ CRP ↔ CHOL, LDL, HDL, TG
[32] 55/20: 11 mild, ↑ MDA ↓
20 moderate ↑ MDA ↓
24 severe ↑ MDA ↓
[33] 7/6 ↑
[34] 16/16 ↑ TBARS ↓
[35] 59/40 ↑ MDA ↑ IL-6
[36] 90/30: 30 mild ↑ MDA ↓
30 moderate ↑ MDA ↓
30 severe ↑ MDA ↓
[37] 39/25 ↑ TOC ↓
[38] 60/47 ↑ peroxides ↓
[39] 32/20 ↔ TBARS
[40] 40/20 ↑ peroxides
[41] 127/389 ↑ peroxides
[42] 100/100: 29 Mild ↑ MDA ↑ CHOL, LDL
↔ HDL, TG
60 Moderate ↑ MDA ↑ CHOL, LDL
↔ HDL, TG
11 Severe ↑ MDA ↑ CHOL, LDL
↔ HDL, TG
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levels were still higher than those of the other group of
patients [46], suggesting a persistent condition of sys-
temic oxidative stress. It was recently reported [35] that
MDA values in psoriatic subjects were similar to those
of patients with coronary artery disease (n = 59) and a
significant positive correlation was found between MDA
and the vascular adhesion protein-1 (VAP-1), involved in
the migration process of lymphocytes into sites of in-
flammation [19]. In this context, it is known that mul-
tiple molecular events, involving ROS generation and
inflammation, are involved in smoking-induced CVD
[10]. In this context, it has been suggested that some
constituents of cigarette smoke (i.e. nicotine, methyl
vinyl ketone, and α,β-unsaturated aldehydes, such as,
acrolein and crotonaldehyde) could be responsible for
NOX-mediated oxidative stress [10]. NOX has been
established as an important source of ROS contributing
to the pathogenesis of CVD [10] and it is well known
that the respiratory burst of leukocytes was abnormally
high in patients with psoriasis [64, 65]. In fact, increased
NOX activity and intracellular production of ROS were
observed in subjects with psoriasis in conjunction with
decreased TAC and increased TBARS [21].
Attawa and Swelam [20] reported a significant increase
in serum MDA and in PASI in smokers compared with
non-smokers, that increased with increasing the pack-
years of smoking. Furthermore, a highly significant dif-
ference in the levels of MDA and PASI score was de-
tected among ex-smoker patients in comparison with
the smoker patients [20]. On the contrary, Emre et al.
Table 1 Case–control studies reporting plasma or serum peroxidation biomarkers and Total Antioxidant Capacity in psoriasis:
association with inflammation and lipid profile (Continued)
[43] ↑ CHOL, TG
30/33 ↑ oxLDL ↑ ESR ↔ LDL
↓ HDL
[44] 24/26 ↑ MDA ↑ IL-8
[45] 90/90: 30 mild ↑ MDA
30 moderate ↑ MDA
30 severe ↑ MDA
[46] 40/40: 34 remission ↔ MDA
6 acute ↑ MDA
[47] 60/30: 30 inactive psoriasis ↑ TBARS ↓ ↔CHOL, LDL, TG
↓ HDL
30 active psoriasis ↑ TBARS ↓ ↑ CHOL, LDL, TG ↓ HDL
[48] 60/40: 30 inactive psoriasis ↑ TBARS ↔ ↑ CRP
30 active psoriasis ↑ TBARS ↓ ↑ CRP
[49] 48/40: 24 inactive psoriasis ↑ TBARS ↔ ↔CHOL, LDL, TG
↓ HDL
24 active psoriasis ↑ TBARS ↓ ↑ CHOL, LDL, TG ↓ HDL
[50] 33/36 ↔
[51] 23/23 ↑ MDA
[52] 45/45 ↑ MDA ↑ CHOL, LDL, ↔ HDL, TG
[53] 40/47 ↑ TOS ↓
[54] 30/23 ↔ MDA ↔ ↔ CHOL, LDL, HDL, TG
[55] 52/25: 25 with MS ↔ TOS ↔ ↑ CHOL, LDL, TG
↓ HDL
27 without MS ↔ TOS ↔ ↔ CHOL, LDL, HDL, TG
[56] 35/35 ↑ MDA, oxLDL ↓ CRP, ESR↑ ↑ CHOL, LDL, TG ↓ HDL
[57] 67/35 ↑ TBARS
[58] 22/22 ↔ MDA
CHOL: cholesterol; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-density lipoprotein; IL: interleukin; LDL: low-density lipoprotein; MDA:
malondialdehyde; MS: metabolic syndrome; oxLDL: oxidized low-density lipoprotein; ROS: reactive oxygen species; TAC: total antioxidant capacity; TBARS: thiobarbituric
acid reactive substance; TG: triglycerides; TOC: total oxidant capacity, also named total oxidant status (TOS); VAP-1: vascular adhesion protein-1; ↑: increased; ↓: decreased;
↔: unchanged
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[30] reported that, despite significantly higher PASI
scores in smoker patients than in non-smoker patients,
TAC and TOS levels were similar between smoker and
non-smoker patients and both smoker and non-smoker
patients had significantly increased TOS levels and de-
creased TAC levels than healthy subjects. Furthermore,
in this study there were no significant correlations be-
tween PASI scores and TAC, TOS, TG and CHOL levels
in patients with psoriasis [30].
Twenty out of fifty-eight case–control comparisons
described also data of lipid profile (Table 1). Only six
studies reported increased levels of TG and decreased
HDL (Table 1) [26, 43, 47, 49, 55, 56], two of which
found high levels of TG only in patients with active
psoriasis [47, 49] and another one only in subjects with
metabolic syndrome (MS) [55]. On the contrary, high
levels of CHOL and LDL were found in 60.0 % of cases
(12/20) and in 55 % of cases (11/20), respectively (Table 1).
The high levels of CHOL were accompanied by an in-
crease in the markers of peroxidation in 91.7 % (11/12) of
cases and by a decrease in TAC only in 60 % (3/5).
Overall case–control studies suggest that markers of
peroxidation are more sensitive indexes of oxidative
stress than TAC, and are more often associated with in-
flammation and dyslipidemia.
Intervention studies
Topical therapy (i.e. corticosteroids, vitamin D3 and its
analogues, calcineurin inhibitors, retinoids, dithranol, tar
and keratolytic agents such as salicylic acid and urea) is
the first line therapy of psoriasis [66]. Phototherapy, in-
cluding ultraviolet (UV) B and photochemotherapy
(psoralen oral or topical with local ultraviolet A,
PUVA) are established treatments for psoriasis that are
used for those patients in whom topical therapy has
failed [66]. On the other hand, ciclosporin and metho-
trexate (MTX) are the most commonly used systemic
therapies to treat psoriasis and will be referred to as
systemic non-biological therapies [66]. Biological ther-
apies have been introduced into the management of
psoriasis. Three TNF-α antagonists (adalimumab, eta-
nercept and infliximab), and the IL12/23 monoclonal
antibody (ustekinumab) are licensed for use in moder-
ate and severe psoriasis [66]. All four agents are ap-
proved for use by National Institute for Health and
Clinical Excellence in people who have failed to respond
to systemic nonbiological therapies including ciclosporin,
methotrexate and PUVA or in subjects intolerant to, or
having a contraindication to these treatments [66].
We performed a review of seventeen interventions,
from thirteen studies (Table 2), regarding topical therapy
[26–28, 33, 57], phototherapy [26, 27, 39, 59], drug treat-
ment [29, 60, 61] and biological treatments [21, 44, 62].
Gavan et al. [33] monitored the level of TAC in 7
males with psoriasis before and after a single applica-
tion of fluocinolone acetonide 0.025 % ointment to
90 % of the body. The results showed that the
plasma level of TAC was significantly increased at
24 h after glucocorticosteroid application. Two other
studies [26, 27] did not find changes in TAC after
long term treatment with calcipotriene (calcipotriol)
or betamethasone dipropionate, or a combination of
the two. Moreover, the authors found a significant
reduction in TBARS, but not in oxLDL and in C re-
active protein (CRP) (Table 2).
Systemic and local immune suppression are involved
in the efficacy of phototherapy regimens such as broad-
band UVB (BB UVB), narrow-band UVB (NB UVB) and
PUVA [67]. Although these therapies reduced CRP in
the majority of the interventions (80 %, 4/5) (Table 2),
both UV radiation and psoralens generate free radicals,
potentially inducing oxidative stress [67]. In the reviewed
studies were observed decreased (2/6) [27], unchanged
(2/6) [26] and increased (2/6) [39, 59] levels of markers
of peroxidation after phototherapy (Table 2). The TAC
decreased only in one of the five interventions (i.e.
PUVA) (Table 2).
Conflicting results came also from treatment with
drugs such as mycophenolate mofetil (MMF, 1 month,
begun in a dosage of 1 g/d and increased over 1 wk to
1.5 to 2.0 g/d administered in two divided doses) [60]
and MTX (7.5 mg per week for 12 weeks [29] or 80 and
160 mg cumulative dosage for 8 weeks [61]) (Table 2).
One study reported that plasma MDA was significantly
increased after MTX treatment of psoriasis patients,
whereas TAC was not significantly changed after
12 weeks of treatment [29]. Another study [61] reported
that there was no statistically significant alteration in
serum levels of TAC and TOS, after 8 weeks of MTX
therapy. The only study that evaluated the effect of
MMF [60] was done only in three patients with psoriasis
who had also grade I essential hypertension (140 to 159/
90 to 99) and reported mild improvement of psoriasis in
two cases and symptoms unchanged in the other.
Among currently available biological drugs for treating
psoriasis, TAC or markers of peroxidation were mea-
sured after treatment with anti-TNF-α biologics (inflixi-
mab via intravenous administration of 5 mg/kg every
8 weeks for 6 months [21] or etanercept subcutaneously
at a dosage of 50 mg biweekly for 12 weeks, followed by
25 mg biweekly for a further 12 weeks [62]) and anti-
CD11a (efalizumab, weekly 1 mg/kg of body weight sub-
cutaneous injections for 12 weeks [44]). All biologics de-
creased markers of peroxidation (100 % 3/3) and
etanercept increased TAC (Table 2). Decreases in ROS
and CRP were reported after infliximab [21] and etaner-
cept [62], respectively.
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Although the higher plasma IL-8 levels, compared to
healthy sunjects, were unchanged after efalizumab treat-
ment, the latter abrogates TNF-α and IFN-γ ex–vivo-in-
duced expression during the mixed leukocyte reaction
[44]. Therefore, in all studies the decrease in peroxida-
tion was accompanied by the decrease of at least one
marker of inflammation.
As observed in case–control studies lipid peroxidation
markers seem to be more sensitive to redox status in
psoriasis.
Concerning lipid profile, only MTX treatment de-
creased CHOL, but this decrease was accompanied by
an increase of the values of alanine aminotransferase
(ALT), suggesting toxic effects of MTX on the liver
Table 2 Intervention studies reporting plasma or serum peroxidation biomarkers and Total Antioxidant Capacity in psoriasis:
association with inflammation and lipid profile
Ref. N° subjects: Treatment Peroxidation TAC Inflammation Lipid profile
Duration (study design)
[33] 7: topical treatmenta ↑
Single application
[28] 67: topical treatmentb ↓ TBARS
20 days
[57] 67: topical treatmentb ↓ TBARS
20 days
[26] 10: topical treatmentc ↓ TBARS ↔ ↔ CRP ↔ CHOL, LDL, HDL, TG
↔ oxLDL
11: NB UVB ↔ TBARS, oxLDL ↔ ↓ CRP ↔ CHOL, LDL, HDL, TG
13: PUVA ↔ TBARS, oxLDL ↓ ↓ CRP ↔ CHOL, LDL, HDL, TG
3, 6, and 12 weeks (3 treatments in parallel)
[27] 10: topical treatmentc ↓ TBARS ↔ ↔ CRP
17: NB UVB ↓ TBARS ↔ ↓ CRP
20: PUVA ↓ TBARS ↔ ↓ CRP
3, 6, and 12 weeks (2 treatments in parallel)
[39] 32: BB UVB ↑ TBARS
21 weeks (longitudinal)
[59] 24: NB UVB ↑ TOS ↔ ↔ CRP
30 sessions (longitudinal)
[60] 3: MMF ↔ MDA ↔ CRP
1 months (longitudinal)
[29] 58: MTX ↑ MDA ↔
6 and 12 weeks (longitudinal)
[61] 26: MTX ↔ TOS ↔ ↓ CHOL, LDL, HDL
8 weeks (longitudinal)
[21] 13: Infliximab ↓ MDA ↔ ↓ ROS
6 months (parallel: treated versus 16 untreated patients)
[62] 23: Etanercept ↓ peroxides ↑ ↓ CRP ↔ CHOL, LDL, HDL, TG
24 weeks (longitudinal)
[44] 24: Efalizumab ↓ MDA ↔ IL-8
12-week (longitudinal) ↓ Ex-vivo TNF-α and IFN-γ
BB UVB: broad-band UVB; CHOL: cholesterol; CRP: C-reactive protein; HDL: high-density lipoprotein; IFN: interferon; IL: interleukin; LDL: low-density lipoprotein;
MDA: malondialdehyde; MMF: mycophenolate mofetil; MTX: Methotrexate; NB UVB: narrow-band UVB; oxLDL: oxidized low-density lipoprotein; PUVA: photochemotherapy;
ROS: reactive oxygen species; TAC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substance; TG: triglycerides; TNF: tumor necrosis factor; TOS: total oxidant
status; Topical treatment: afluocinolone acetonide, bsalicyl ointment, cignoline, tar, followed by bethametasone dipropionide with salicyl acid, ccalcipotriene (calcipotriol) or
betamethasone dipropionate, or a combination of the two; ↑: increased; ↓: decreased;↔: unchanged
Peluso et al. Journal of Biomedical Science  (2016) 23:52 Page 6 of 13
[61]. On the other hand, lipid profile did not change
after 24 weeks of treatment with etanercept, despite the
improvement of redox status, and the decrease of CRP
[62] (Table 2).
Although overall the reviewed intervention studies
(Table 2) suggest that biological drugs could be the bet-
ter choice in the treatment of psoriasis, they do not im-
prove dyslipidemia. In this context, Saraceno et al. [68]
did not find significant changes in plasma CHOL, LDL,
HDL and TG in patients with psoriasis after 48 weeks of
treatment with anti-TNF-α (infliximab, etanercept and
adalimumab) and efalizumab, whereas a significant in-
crease in the mean body mass index was observed. From
that, probably the use of anti-TNF-α should be associ-
ated to an energy-restricted diet in order to improve
psoriasis symptoms and lipid profile [69] and to prevent
the weight gain [70].
Discussion
Both case–control and intervention studies suggested
that marker of peroxidation could be a more sensitive
index of oxidative stress than TAC. As previously ob-
served and suggested, lipid peroxidation resulted unre-
lated to TAC, probably because the latter often measures
the antioxidant capacity in hydrophilic environment [63].
This could account to the fact that markers of peroxida-
tion are more often associated with dyslipidemia (Fig. 1),
but does not explain the association with the inflamma-
tory markers (Fig. 1). However, limitations of the reviwed
studies must be taken into account in the interpretation of
the results. Furthermore, some methodological consider-
ation should be made and the relationship between cellu-
lar and plasma oxidative stress must be taken into account
for properly evaluating the clinical significance of TAC
and peroxidation biomarkers in psoriasis.
Methodological limitations and clinical significance
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Fig. 1 Case–control (a) and intervention studies (b) suggested that marker of peroxidation could be a more sensitive index of oxidative stress
than total antioxidant capacity (TAC). However, some methodological limitations and the relationship between cellular and plasma oxidative
stress must be taken into account to properly evaluate the clinical significance of TAC and peroxidation biomarkers in psoriasis (c). TAC methods
are strongly influenced by the presence of products of catabolism, such as uric acid and bilirubin, the latter is able to react with thiobarbituric
acid (TBARS). The clinical significance of methods based on redox reactions with metal ions must consider the potential detrimental effect of
reduced metals in conditions of low levels of antioxidant enzymes (c). The latter, as well as the inflammatory cytokines are regulated at transcriptional
levels by cellular redox status. ↑: increased, ↓: decreased/:or↔: unchanged; ARE: antioxidant responsive elements; CAT: catalase; CHOL: cholesterol;
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Limitations of the reviwed studies
A possible explanation of the conflicting data of the
reviwed studies could be found in the potential limita-
tions of the these studies.
First of all, the number of patients in individual trials
ranged from 3 to 127 (Table 1 and Table 2). The small
number of subjects analized in many studies could be
below the sample size needed to give an information of
both normal range in healthy subjects [25, 33, 34] and
oxidative stress in psoriasis before and after treatments
[21, 25–27, 60].
Secondly, the included trials varied in terms of study
population. The duration of psoriasis sometimes ranged
between few months (1–2) and many years (more than
20). In particular Baz et al. [23] reported a duration of
the disease ranging between 1 month and 30 years and
Coimbra et al. [27] between 2 months and 55 years. Fur-
thermore, PASI score was very variable. For example
Attwa et al. [20] reported PASI of 13.8 ± 5.9 in non-
smokers and of 34.36 ± 11.8 in smokers, whereas Emre
et al. [30] reported PASI of 11.09 ± 4.99 in non-smokers
and of 16.35 ± 10.94 in smokers.
Also, when patients were stratified for disease activity
the PASI score cut off for considering mild, moderate
and severe psoriasis was very variable. Some Authors
[22, 38] considered PASI < 3 or <7, between 3/7 and 10/
12, and >10/12 as mild, moderate and severe psoriasis,
while other Authors [32, 42, 45] used the cut off of
PASI < 20 or <25, between 20/25 and 49, and >50 as
mild, moderate and severe psoriasis.
Again, short duration of follow-up and study design
could affect the results of the intervention studies. In
particular, for the parallel design studies (treated ver-
sus untreated patients or different treatments), the
small sample sizes could have led to ineffective
randomization and potential confounding, while in
longitudinal (non controlled) trials it is difficult to
draw any firm conclusion.
Finally, although investigators often excluded individ-
uals with any other systemic diseases (diabetes mellitus,
abnormal lipid profile, cardiovascular, kidney and/or
liver diseases) [18–24, 28–32, 36–40, 61], the wash-out
period (treatment free period before blood collection)
was very variable (2 weeks - 6 months) [20, 21, 23, 27,
29–32, 36–40, 44, 59, 61]. Furthermore, only few studies
specified that subjects did not receive lipid-lowering
drugs [31] or antioxidant and vitamin supplements
[20, 31, 37, 39, 40, 59]. In particular, Ikonomidis
et al. [35] reported that all patients with psoriasis
received treatment with cyclosporine 2.5-3 mg/kg
daily. In addition, some subjects had hypertension,
dyslipidemia and were treated with β-blockers,
angiotensin-converting enzyme inhibitors, calcium
channel blockers, diuretics and statins [35].
Methodological consideration on peroxidation
biomarkers and total antioxidant capacity
All the reviewed studies used old markers, such as per-
oxides, dienes, TBARS or MDA, that are progressively
being replaced by new one isoprostanes [71] and all
studies measured TAC by using a single assay, which im-
poses the chemical limitations of that assay [72, 73].
Antioxidant activity can be monitored by a variety of
assays with different mechanisms, including hydrogen
atom transfer (HAT), single electron transfer (SET) and
reducing power, among others [74, 75]. Oxygen radical
antioxidant capacity (ORAC) is the most common HAT
method and other similar HAT-based methods sharing
the same principle and common features of ORAC assay
include total radical trapping antioxidant parameter
(TRAP) and crocin bleaching assays [74].
In these methods the peroxyl radical produced by a
generator reacts with a probe resulting in the loss of
fluorescence or absorbance, that are recorded by decay
curves [74]. Commonly used peroxyl radical generators
include a group of azo compounds such as the hydrophilic
2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH)
and the lipophilic 2,2′-azobis(2,4-dimethylnaleronitrile
(AMVN). A standard antioxidant, usually Trolox (a vita-
min E analogue), is used as reference and ORAC values of
the tested antioxidants are reported as Trolox equivalents
[74]. Also SET-methods typically used Trolox as standard
antioxidant [74]. The Trolox equivalent antioxidant cap-
acity (TEAC) assay is the most used method in the
reviewed studies and is classified as SET-based method
[74]. The assay measures the ability of antioxidants to
scavenge the stable radical cation 2,2′-azinobis(3-ethyl-
benzothiazoline-6-sulphonic acid (ABTS), a blue-green
chromophore with maximum absorption at 734 nm which
decreases in its intensity in the presence of antioxidants
[74]. Similarly 2,2-Diphenyl-1-picrylhydrazyl (DPPH) is a
stable chromogen radical with a deep purple colour [74].
The reducing power of antioxidants is measured
through redox reaction with various metal ions, such as
iron (ferric reducing antioxidant potential, FRAP), and
copper (Cupric reducing antioxidant capacity, CUPRAC)
[74]. Also the methods of Erel et al. for the measure of
TAS and TOS/TOC involve oxido-reduction of iron
[76, 77]. The TOS/TOC assay is based on the oxidation
of ferrous ion to ferric ion in the presence of various
oxidant species in acidic medium and the measurement
of the coloured complex ferric ion-xylenol orange [76].
The TAS/TAR assay is based on the production of hy-
droxyl radical via Fenton reaction, and the rate of the
reactions was monitored by following the absorbance of
coloured dianisidyl radicals. The mixture of ortho-
dianisidine, ferrous ammonium sulfate and hydrogen
peroxide solution produced oxidized o-dianisidine mol-
ecules into dianisidyl radicals, leading to a bright
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yellow-brown colour development and antioxidants
suppressed the colour formation [77]. The TOS/TOC
assay is calibrated with hydrogen peroxide and results
are expressed in terms of micromolar of hydrogen per-
oxide equivalent per litre (μmol H2O2 Eq/l) [76], whereas
the TAS assay is calibrated with a stable antioxidant stand-
ard solution, which is traditionally the Trolox, and results
were expressed as mmol Trolox Eq/l [77].
Although different TAC assays sometimes did not cor-
relate with each other [73], even considering the same
method or methods with similar mechanisms, the results
were conflicting.
Both decreased [34, 37, 53, 56] and unchanged [54, 55]
TAC levels were reported by using TAS method. When
TAC was evaluated by TEAC neither significant corre-
lations with PASI scores [30] nor differences between
active and inactive psoriasis were reported [48, 49]. Al-
though severity wise decrease in TAC levels, by using
crocin bleaching [32], both increased [62] and un-
changed [21] ORAC values were reported after anti-
TNF-α treatment. Severity wise decrease in TAC levels,
measured by FRAP [36] but not by CUPRAC [22].
TAC methods are strongly influenced by the presence
of products of catabolism, such as bilirubin and uric acid
[78] (Fig. 1). Although the role of uric acid and bilirubin
in the prognosis of oxidative stress-related pathologies is
still controversial [79, 80], hyperuricemia affected 20 %
of patients with psoriasis [81] and high levels of bilirubin
were found in some of the reviewed cases, probably due
to red blood cells’ damage [27, 47]. Either decreased [47]
or unchanged [27] TAC values in patients with psoriasis
as compared with healthy subjects were reported. In
addition, Severin et al. [50] found increased levels of
both bilirubin and urate and TAC values that did not
differ from controls. High level of bilirubin could not
only underestimate oxidative stress assessed with TAC
methods, but also overestimate oxidative stress by using
TBARS assay (Fig. 1). In fact, it is known that bilirubin,
as well as other compounds like sugars or amino acids,
is able to react with thiobarbituric acid [75]. From that,
the interference of bilirubin and uric acid must be taken
into account both in the interpretation of the results and
in the evaluation of the clinical significance of TAC and
TBARS (Fig. 1).
On the other hand, increased levels of TOS were re-
ported [30, 37, 53].
Regarding the relationship between cellular and plasma
TAC and markers of lipoperoxidation, Barygina et al. [21]
found higher levels of TBARS and lower levels of ORAC
in both plasma and cell lysates of white blood cells. Be-
sides, the increase of TBARS and the decrease of ORAC,
were accompanied by an increase of protein carbonyl con-
tent (marker of oxidative protein damage) in plasma and
by an increase of the redox glutathione ratio (GSSG/GSH)
and of the cellular lipoperoxidation estimated using the
fluorescent dye 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-
4-bora-3a,4a-diaza-s-indacene-3-undecanoic acid (BOD-
IPY 581/591 C11) [21]. In addition, the NOX activity and
the intracellular ROS, measured with the fluorescent dye
dihydrochlorofluorescein diacetate (H2DCF-DA), were
also higher in psoriatic patients [21]. Furthermore, all
these markers were improved after anti-TNF-α treatment.
Therefore, although the limitations of TAC and plasma
peroxidation markers, they reflect the cellular radical
damage induced by oxidative burst.
Relationship between cellular and plasma oxidative
stress: metal redox status affects antioxidant enzymes
Antioxidant enzymes have a significant impact on the
redox status, which is not reflected in the assays of iso-
lated plasma [73]. In fact, antioxidant defenses of the
body are composed of molecular and enzymatic players;
however, the composition of the network markedly dif-
fers in terms of concentration and components in differ-
ent environments [8]. Protection at the cellular level is
mainly guaranteed by enzymes, whereas in plasma, non-
enzymatic antioxidants (including low-molecular weight
compounds such as uric acid, bilirubin, thiols, vitamin E,
ascorbic acid, and carotenoids) play the major role [8]. The
latter were measured by TAC methods, but their relation-
ship with cellular antioxidants is often a neglected aspect.
Superoxide dismutase (SOD) catalyzes the one-electron
dismutation of superoxide into hydrogen peroxide and
oxygen; catalase (CAT) then operates the two electron-
dismutation into oxygen and water [8, 16] (Fig. 1). Gluta-
thione peroxidase (GPX) is involved not only in hydrogen
peroxide removal but also in converting lipid hydroperox-
ides into their corresponding alcohols [8].
In the reviewed studies, data on antioxidant en-
zymes are controversial. Although CAT or SOD were
decreased in the majority of the studies [20, 28, 29,
32, 36, 40–42, 45, 56, 58], these enzymes were un-
changed in one study [47] and increases were re-
ported in CAT [40, 41] or SOD [23, 33]. Gavan et al.
[33] found increased levels of SOD in patients with
psoriasis, which were significantly decreased after
glucocorticosteroid application, despite the increase
of TAC. Although superoxide production was higher
in both patients with severe erythrodermic (EPS) and
arthropathic (PSA) forms of psoriasis, increased SOD
and CAT levels were found in EPS, and decreased
SOD levels were found in arthropathic PSA forms of
psoriasis [82], suggesting that only severe forms of
psoriasis are associated with decreased enzymatic
antioxidant defences. In fact it has been reported that
the blood SOD level decreased significantly with in-
creasing severity of psoriasis [20].
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In addition it has been found that the activity of blood
CAT increased, and activity of blood SOD decreased
with increasing severity of psoriasis [40].
On the other hand, although decreases of GPX have
been reported in psoriasis [45, 56–58], it has been re-
ported that only the group of patients who did not re-
spond to the treatment with efalizumab selectively
showed a peculiar up-regulation of polymorphonuclear
cells (PMN)-associated GPX after 12-week, both when
compared to GPX levels of the same group of patients
before treatment and also when compared to GPX levels
of the groups of responders at the same time-point [44].
In addition, CAT activity in PMN was significantly lower
in this group of patients after 12-week when compared
to responders at the same time-point, whereas SOD
remained unchanged [44]. When examined in erythro-
cytes, the high baseline GPX was found significantly re-
duced exclusively in the responding patients following a
12-week therapy, but no relevant changes were found in
the other antioxidant enzymes [44]. Therefore, Pastore
et al. [44] suggested that high hydroperoxide levels are
involved in psoriasis persistence. Also Matoshvili et al.
[41] suggested that the statistically significant increase in
the activity of CAT in psoriatic patients reflects a high
concentration of peroxides.
In this context it is known that SOD, CAT and GPX
are regulated at transcriptional levels by cellular redox
status, through a mechanism that involves the inter-
action between the antioxidant responsive elements
(ARE) and the nuclear factor-erythroid 2-related factor 2
(Nfr2) [83, 84] (Fig. 1). Under physiological conditions,
Nfr2 is bound to kelch-like ECH-associated protein-1
(Keap1) and thereby sequestered in the cytoplasm,
whereas under conditions of oxidative stress, Nfr2 disso-
ciates from Keap1, translocates to the nucleus and in-
duces the transcription of antioxidant enzymes. The
cysteine residues on Keap1, which are ultrasensitive to
electrophiles, are critically important for the binding
with Nrf2 [83].
Also nuclear factor- kappa B (NF-kB) is activated by
ROS, through the degradation of its inhibitor IkB, and
then migrates to the nucleus stimulating the expression
of its target genes, such as inflammatory cytokines [84]
(Fig. 1). The common mechanisms of activation and the
interplay between Nfr2 and NF-kB have been reviewed
and it has been suggested a potential concerted modu-
lation of antioxidant and inflammatory pathways via
upstream mitogen-activated protein kinases (MAPK)
[84]. MAPK [85] and NK-kB [86] have a pathogenic
role in psoriasis.
It is well known that iron and copper could induce
both NF-kB and Nfr2 pathways, through production
of ROS [87–94] (Fig. 1). Increased levels of copper
[95, 96] and free reactive iron [34] were found in
psoriatic patients. When comparison of copper data
was done between groups of psoriasis severity, a sig-
nificant difference was found between mild, moderate
and severe groups [96].
Within TAC methods, FRAP and CUPRAC matches
the antioxidant capacity to the reducing ability [74, 75]
and also the methods of Erel for the measure of TAS
and TOS/TOC are based on the iron redox status
[76, 77] (Fig. 1). Although reducing and antioxidant
capacity are related, it must be taken into account
that hydroxyl radical, the initiator of the lipid peroxida-
tion, is produced from the reaction between reduced iron
or copper and hydrogen peroxide [75] (Fig. 1).
Therefore, a decrease in the metal reducing power
could be more likely beneficial than detrimental in con-
ditions of high levels of copper or iron and low levels of
antioxidant enzymes (such as psoriasis).
Conclusion
Psoriasis is associated with systemic oxidative stress.
Overall the reviewed case–control (Table 1) and inter-
vention (Table 2) studies suggest that peroxidation
markers are more sensitive than TAC in the evaluation
of oxidative stress in psoriasis (Fig. 1). Furthermore, it
seems that biological drugs could be the better choice in
the treatment of psoriasis (Fig. 1). However, in this re-
view we pointed out the limitations of TAC and plasma
peroxidation markers and the low clinical significance in
cases of high levels of bilirubin, uric acid, copper or iron
and low levels of antioxidant enzymes (Fig. 1).
Concerning other possible markers of oxidative stress,
the ischaemia-modified albumin (IMA), as detected
using the albumin cobalt-binding test, was registered by
the United States Food and Drug Administration as a
marker of myocardial ischemia and has been evaluated
in two cross-sectional studies in psoriasis [97, 98]. IMA
levels were higher in patients with psoriasis than in
healthy subjects [97, 98] and showed a significant posi-
tive correlation with PASI score [97]. However, it has
been pointed out that further studies for normal popula-
tion distributions by gender and ethnicity, and an
optimum cut-off value are still required for IMA [99].
In conclusion our review suggests that new methods
should be developed in order to evaluate systemic oxida-
tive stress in psoriasis.
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